The rise and evolving role of Fusobacterium nucleatum subspecies Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read MoreI am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Microbes
Microbes
Microbes are microscopic organisms living in and on the human body, shaping health through digestion, vitamin production, and immune protection. When microbial balance is disrupted, disease can occur. This guide explains key microbe types—bacteria, viruses, fungi, protozoa, and archaea—plus major pathogenic and beneficial examples.
-
Divine Aleru
Read More
Researched by:
-
Divine Aleru
ID
Divine Aleru
Read More
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What was studied?
This study examined the impact of Fusobacterium nucleatum (F. nucleatum) on colorectal cancer (CRC) chemoresistance, specifically its role in modulating the autophagy pathway. The researchers aimed to understand how F. nucleatum influences CRC cells’ response to chemotherapy, with a particular focus on the activation of autophagy and its contribution to chemoresistance.
Who was studied?
The study focused on CRC cell lines (including HCT116 and HT29) cultured with F. nucleatum. The research was also extended to xenograft mouse models to investigate tumor growth and chemoresistance in vivo. Additionally, CRC patient tissues were analyzed to correlate F. nucleatum levels with clinical outcomes such as recurrence and survival.
What were the most important findings?
The study found that F. nucleatum significantly contributes to chemoresistance in CRC by activating the autophagy pathway. The bacterium increased the expression of autophagy-related proteins such as ULK1 and ATG7 and reduced the effectiveness of chemotherapy agents like Oxaliplatin and 5-FU. Co-culture of CRC cells with F. nucleatum prevented chemotherapy-induced apoptosis, indicating that autophagy plays a crucial role in this process. Moreover, F. nucleatum was found to suppress the expression of miR-18a* and miR-4802, which are associated with autophagy regulation. These findings were supported by both in vitro assays and in vivo mouse models. Importantly, high levels of F. nucleatum in CRC tissues were associated with worse patient outcomes, including recurrence post-chemotherapy.
What are the greatest implications of this study?
This study suggests that Fusobacterium nucleatum enhances CRC chemoresistance through autophagy activation, making it a potential target for therapeutic intervention. The research highlights the importance of understanding the microbiome’s role in cancer therapy resistance, which could lead to new strategies for overcoming chemoresistance in CRC. The findings also emphasize the potential of targeting the autophagy pathway and specific microRNAs to improve treatment efficacy in CRC patients, particularly those with high F. nucleatum levels.